Cicor Technologies Ltd. (SWX:CICN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 594.89M |
| Revenue (ttm) | 616.50M |
| Net Income (ttm) | 16.91M |
| Shares Out | 4.40M |
| EPS (ttm) | 3.73 |
| PE Ratio | 36.25 |
| Forward PE | 17.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,211 |
| Average Volume | 15,356 |
| Open | 136.00 |
| Previous Close | 137.80 |
| Day's Range | 134.20 - 137.20 |
| 52-Week Range | 101.00 - 229.00 |
| Beta | 0.58 |
| RSI | 55.10 |
| Earnings Date | Apr 14, 2026 |
About Cicor Technologies
Cicor Technologies Ltd., together with its subsidiaries, develops, and manufactures electronic components, devices, and systems internationally. The company operates in two segments: Electronic Manufacturing Services (EMS) and Advanced Substrates (AS). It offers engineering services, such as test engineering, product, test development, and process engineering services; electronic manufacturing services, including printed circuit board (PCB) assembly, cable assembly, box building, and microelectronic assembly; precision plastics, such as tool de... [Read more]
Financial Performance
In 2025, Cicor Technologies's revenue was 616.50 million, an increase of 28.21% compared to the previous year's 480.84 million. Earnings were 16.91 million, a decrease of -37.95%.
Financial StatementsNews
Cicor Technologies Earnings Call Transcript: Q4 2025
Sales rose 28% to CHF 660 million, driven by five acquisitions and strong order intake. Adjusted EBITDA reached CHF 65 million, with robust free cash flow and moderate leverage. 2026 guidance targets CHF 700–750 million in sales and CHF 70–80 million Adjusted EBITDA.
Cicor Technologies Transcript: M&A Announcement
The acquisition creates the largest global pure-play EMS provider in high-mix, low-volume segments, with a strong focus on healthcare, aerospace, and industrial automation. The deal is expected to deliver significant cost synergies, EPS accretion, and enhanced global reach, with closing anticipated in H1 2026.
Cicor Technologies Transcript: M&A Announcement (Media)
The acquisition will create the largest global pure-play EMS provider in the high-mix, low-volume segment, doubling revenue and delivering significant cost synergies. The deal is highly accretive, with strong stakeholder support, a proven integration approach, and a focus on long-term growth.
Cicor Technologies Earnings Call Transcript: H1 2025
Record H1 2025 revenue and EBITDA were driven by acquisitions and a return to organic growth in Q2. Raised full-year guidance reflects strong operational momentum, despite FX headwinds and one-time integration costs from Éolane.
Cicor Technologies Earnings Call Transcript: H2 2024
Record 2024 results with revenue up 23% and EBITDA margin improvement, driven by acquisitions and market share gains in core sectors. Guidance for 2025 anticipates CHF 520–560 million in sales, with further growth potential from pending M&A.
Cicor Technologies Transcript: CMD 2024 Presentation
Strategy 2028 aims for pan-European leadership in electronics design and manufacturing, focusing on high-growth verticals and a CDMO model. Strong organic and M&A-driven growth, operational excellence, and disciplined capital allocation underpin targets of CHF 1 billion revenue and 15% ROIC by 2028.
Cicor Technologies Earnings Call Transcript: H1 2024
Revenue and EBITDA reached record highs, driven by acquisitions and margin improvements, despite a challenging environment. Guidance for full-year sales and EBITDA was raised, with strong outlooks in aerospace, defense, and medical sectors.